The Beauty Health Company (SKIN) Reports Q3 Loss, Tops Revenue Estimates
Beauty Health (SKIN) delivered earnings and revenue surprises of -12.50% and +2.84%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
How this was made

The 30-second read
Why it matters
The mixed results suggest cautious trading; technical analysis and broader market trends should be considered for timing decisions.
Market read
Limited immediate impact on the broader market; primarily affects stakeholders and investors in SKIN and related sectors.
What to watch
Potential upcoming product launches or strategic initiatives not reflected in current earnings could alter the outlook.
Background
Beauty Health (SKIN) reported Q3 earnings with a 12.50% earnings miss but a 2.84% revenue beat, indicating mixed financial health amid challenging market conditions.
Ticker impact
The company's recent earnings report shows a mixed financial performance, with a 12.50% earnings miss but a 2.84% revenue beat, indicating some resilience but underlying challenges.
Potential short-term sideways movement with slight downward bias due to earnings miss, but revenue beat may provide support.
The mixed financial results create uncertainty; technical indicators and broader market conditions will influence actual price movement.
Market effects
The results may temper investor enthusiasm in the life sciences and beauty sectors, leading to cautious trading in related stocks.
Limited regional impact; primarily affecting US-based beauty and health companies.
Minimal global market influence; company-specific news.
Counterpoint
The earnings miss might be an anomaly; if revenue growth sustains, the stock could rebound in the medium term.
Key entities
- CompanyBeauty Health Company
A provider of beauty and health products and services.
